A selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaro inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.
Nonvalvular Atrial Fibrillation, Treatment of DVT and/or PE, Reduction in the Risk of Recurrence of DVT and/or PE, Prophylaxis of DVT Following Hip or Knee Replacement Surgery, Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications, CAD or PAD
DOSAGE AND ADMINISTRATION:
Nonvalvular Atrial Fibrillation: 15 or 20 mg, once daily with food.
Treatment of DVT and/or PE: 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment.
Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE: 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment.
Prophylaxis of DVT Following Hip or Knee Replacement Surgery: 10 mg orally once daily with or without food. Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding: 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days.
CAD or PAD: 2.5 mg orally twice daily with or without food, in combination with aspirin (75-100 mg) once daily.
If you are 75 years of age or older. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking rivaroxaban. Your doctor may tell you to stop taking rivaroxaban before the surgery or procedure
Rivaro 2.5mg tablets in pack of 2 x 14`s
Rivaro 10mg tablets in pack of 1 x 10`s
Rivaro 15mg and 20mg tablets in pack of 2 x 14`s